Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.285 per share.
- Total Volume: 7,505.185 shares.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Mr. S A Hussain, President of Global Pharmaceuticals. This change resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Performance Share Plan. No material changes to the company's overall financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of an executive share transaction.
Investor Verification Points
- Verify the total number of shares held by Mr. S A Hussain following this transaction to assess total executive exposure.
- Confirm the dividend reinvestment terms of the 2009 Performance Share Plan to understand the mechanics of the share increase.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial metrics.